Summary by Moomoo AI
iBio Inc, a biotechnology company specializing in AI-driven biologics, has not reported any revenue for the third quarter of Fiscal 2024. The company's financial performance shows a net loss from continuing operations of approximately $4.5 million, or $2.42 per share, for the quarter ended December 31, 2023. This is a decrease from the net loss of approximately $10.6 million, or $21.54 per share, for the same period in the previous year. Research and Development (R&D) expenses decreased by approximately $1.3 million, primarily due to in-house task performance and reduced spending on consultants. General and Administrative (G&A) expenses also decreased by approximately $4.8 million, mainly due to reduced personnel costs and lower consultancy expenses. The company's total operating expenses for the quarter were approximately...Show More